课题基金 / 基金详情

CONSTRUCTION AND OPTIMIZATION OF ANTI-HIV RIBOZYMES

CONSTRUCTION AND OPTIMIZATION OF ANTI-HIV RIBOZYMES
抗HIV核酶的构建和优化
批准号:
3144876
负责人:
JOHN MacKenzie BURKE
金额:
$14.41万
依托单位国家:
美国
项目类别:
财政年份:
1990
资助国家:
美国
项目状态:
已结题
起止时间:
1990-07-01 至 1995-04-30

项目摘要

项目成果

JOHN MacKenzie BURKE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
There is an urgent need for effective therapeutic agents against human immunodeficiency virus 1 (HIV-1), the causative agent of acquired immunodeficiency syndrome (AIDS). This project will result in the development of ribozymes that will selectively attack and destroy HIV RNA within an infected cell. Ribozymes are catalytic RNA molecules; many catalyze site-specific RNA cleavage reactions. The molecular basis for substrate selectivity is understood for some ribozymes. Therefore, it is possible to rationally alter the substrate specificity of a ribozyme by engineering changes within its substrate binding site using recombinant/synthetic DNA methods. The Specific Aims of this proposal are to (1) Develop and characterize ribozymes that selectively attack several HIV-1 RNA sequences, (2) Assemble and evaluate multivalent ribozymes against HIV-1 RNA, (3) Develop a bacteriophage system for analyzing and optimizing antiviral activity of ribozymes in vivo, (4) Use the bacteriophage system for surrogate genetic enrichment of optimized anti-HIV ribozymes, and (5) Evaluate the activity of resulting monovalent and multivalent anti-HIV ribozymes in T cell extracts. Ribozymes for this study will be derived from the self-cleaving "hairpin" minus strand of tobacco ringspot virus satellite ((-)sTRSV). In preliminary work, we have generated a hairpin ribozyme that selectively attacks HIV-1 pol sequences. Advantages of anti-HIV ribozymes are several: (i) Ribozymes can potentially inhibit HIV infection of cells and also inhibit HIV gene expression within infected cells, (ii) Ribozymes may be highly selective agents, (iii) Ribozymes act catalytically, so that a single molecule of ribozyme can potentially destroy many molecules of HIV RNA, and (iv) Ribozymes are not susceptible to pleiotropic drug resistance. This project will directly address major challenges in the development of optimal anti-HIV ribozymes---to achieve the optimal balance of sequence selectivity, catalytic activity and ribozyme stability under conditions encountered in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hammerhead Ribozyme: Active Site Assembly and Structure
Enhancing Protections through Learner-Centered Education
Hammerhead Ribozyme: Active Site Assembly and Structure
Hammerhead Ribozyme: Active Site Assembly and Structure
国内基金
海外基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
  • 批准号:
    31871817
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    孙爱东
  • 依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
  • 批准号:
    81873549
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    刘玉兰
  • 依托单位: